-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 27th, Sansheng Guojian issued an announcement stating that the company received the "Notice of Drug Clinical Trial Approval" approved and issued by the State Food and Drug Administration, approving the company's bispecific antibody injection SSGJ-706 to develop in advanced solid tumors and recurrences.
The current anti-PD1 monoclonal antibody/anti-PDL1 monoclonal antibody single agent and combination chemotherapy have shown superior efficacy than previous standard treatments in many tumor fields
SSGJ-706 is a recombinant bispecific antibody developed by Sansheng Guojian using the bispecific antibody platform with independent intellectual property rights.